192 related articles for article (PubMed ID: 10746802)
21. Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia.
Siems W; Carluccio F; Grune T; Jakstadt M; Quast S; Hampl H; Sommerburg O
Clin Nephrol; 2002 Jul; 58 Suppl 1():S20-5. PubMed ID: 12227722
[TBL] [Abstract][Full Text] [Related]
22. The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients.
Meierhenrich R; Jedicke H; Voigt A; Lange H
Clin Nephrol; 1996 Feb; 45(2):90-7. PubMed ID: 8846536
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
24. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
26. The influence of the hemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients.
Valentini J; Grotto D; Paniz C; Roehrs M; Burg G; Garcia SC
Biomed Pharmacother; 2008; 62(6):378-82. PubMed ID: 18166291
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
García Martín F; Carrascosa Vallejo T; Martín Escobar E; Val Begueria J; Martín Hernández R; de Arriba G; Teno C; Salvatierra J
Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
[TBL] [Abstract][Full Text] [Related]
28. The effect of high-flux hemodialysis on renal anemia.
Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
[TBL] [Abstract][Full Text] [Related]
29. Anemia management and treatment response in patients on hemodialysis: the MAR study.
Portolés J; López-Gómez JM; Aljama P
J Nephrol; 2006; 19(3):352-60. PubMed ID: 16874697
[TBL] [Abstract][Full Text] [Related]
30. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease.
Fishbane S
Blood Purif; 2007; 25(1):53-7. PubMed ID: 17170538
[TBL] [Abstract][Full Text] [Related]
31. [Optimal therapy with erythropoietin (EPO) in patients with renal anemia on hemodialysis therapy].
Merta M; Sobotová D; Zahálková J; Bitterová Z; Jirka T; Knetl P; Kopenec J; Suchanová J; Vlasák J
Sb Lek; 2001; 102(1):41-52. PubMed ID: 11830918
[TBL] [Abstract][Full Text] [Related]
32. Effect of epoetin zeta for correction of renal anemia in hemodialysis patients with thalassemia minor.
Kumchev E; Koytchev R; Dimitrakov D; Stavrev P; Tsochev G; Siebert-Weigel M
Adv Ther; 2008 Dec; 25(12):1375-8. PubMed ID: 19043680
[TBL] [Abstract][Full Text] [Related]
33. Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis.
Uzum A; Toprak O; Gumustas MK; Ciftci S; Sen S
J Nephrol; 2006; 19(6):739-45. PubMed ID: 17173246
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
Cremagnani L; Cantalamessa L; Orsatti A; Vigna L; Vallino F; Buccianti G
Clin Nephrol; 1993 May; 39(5):282-6. PubMed ID: 8513607
[TBL] [Abstract][Full Text] [Related]
35. Oxidative stress and delta-ALA-D activity in chronic renal failure patients.
da Silva AC; Rocha JB; Morsch AL; Zanin RF; Kaizer R; Maldonado PA; Arantes LC; Silva LA; Morsch VM; Schetinger MR
Biomed Pharmacother; 2007; 61(2-3):180-5. PubMed ID: 17383846
[TBL] [Abstract][Full Text] [Related]
36. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of once-weekly intravenous administration of epoetin-beta as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study.
Shigematsu T; Takami H; Shimizu T; Shimoyama H; Kim S; Hirose S; Sakai T; Kono T; Mochizuki T; Nishio K; Degawa H; Motomiya Y
Ther Apher Dial; 2008 Dec; 12(6):469-74. PubMed ID: 19140845
[TBL] [Abstract][Full Text] [Related]
38. Oxidation parameters in complete correction of renal anemia.
Ludat K; Sommerburg O; Grune T; Siems WG; Riedel E; Hampl H
Clin Nephrol; 2000 Feb; 53(1 Suppl):S30-5. PubMed ID: 10746803
[TBL] [Abstract][Full Text] [Related]
39. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
[TBL] [Abstract][Full Text] [Related]
40. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients.
De Vecchi AF; Bamonti F; Novembrino C; Ippolito S; Guerra L; Lonati S; Salini S; Aman CS; Scurati-Manzoni E; Cighetti G
Nephrol Dial Transplant; 2009 Aug; 24(8):2524-9. PubMed ID: 19264746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
